| Year | Firm | Client | Income | Doc |
|---|---|---|---|---|
| 2022 2nd Quarter - Report |
KING & SPALDING LLP | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | $10,000 | |
| 2022 1st Quarter - Report |
KING & SPALDING LLP | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | $10,000 | |
| 2022 AMENDED |
KING & SPALDING LLP | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | — | |
| 2022 Registration |
KING & SPALDING LLP | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | — |